U40 心不全ネットワーク企画セッション Round Table Discussion 11
3月27日［土］16:50-18:20
|
| |
| |
HFpEF phenotyping: is it possible and
clinically important?
|
|
|
| |
| |
|
|
| |
Although the management of heart failure with reduced ejection fraction (HFREF) has improved significantly over the last two decades, little progress has been made in effective treatments for heart failure with preserved ejection fraction (HFPEF). Incomplete understanding of pathophysiology may be the possible reasons why clinical trials have largely failed to show improved outcomes in HFPEF patients. The objective of this session is to overview/discuss the current understanding of pathophysiology, and possibility and implications of phenotyping/phenomapping of HFPEF that may subsequently lead to better treatment and outcomes.
|
|
|
| |
| |
|
|
| |
| |
 |
|
Yuya Matsue
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo
|
|
 |
|
Takeshi Kitai
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe
|
|
|
| |
| |
|
|
| |
| |
 |
|
Jasper Tromp
National Heart Centre Singapore, Singapore
|
|
 |
|
Masaru Obokata
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi
|
|
|
| |
| |
 |
|
Matteo Cameli
Department of Medical Biotechnologies, Section of Cardiology, University of Siena, Siena, Italy
|
|
 |
|
Jin Joo Park
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
|
|
|
| |
| |
|
|